(Q35581950)

9 August 2017

1 reference

title

Infections and anti-tumor necrosis factor alpha therapy (English)

1 reference

9 August 2017

Infections and anti–tumor necrosis factor α therapy (English)

1 reference

31 March 2024

1 reference

31 March 2024

1 reference

31 March 2024

3

Michael E Weinblatt

1 reference

9 August 2017

Todd Ellerin

1

1 reference

9 August 2017

Robert H. Rubin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14613261

reference URL

31 March 2024

language of work or name

1 reference

1 November 2003

1 reference

full work available at URL

9 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.11301

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14613261

reference URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.11301

31 March 2024

1 reference

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.11301

31 March 2024

1 reference

31 March 2024

published in

Arthritis & Rheumatology

1 reference

9 August 2017

Arthritis and Rheumatism

48

11

3013–22

November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14613261

reference URL

31 March 2024

volume

48

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

3013-3022

1 reference

Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept

9 August 2017

cites work

2

1 reference

The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies

31 March 2024

3

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

31 March 2024

5

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2024

6

1 reference

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

31 March 2024

7

1 reference

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

31 March 2024

8

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2024

9

1 reference

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

31 March 2024

10

1 reference

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

31 March 2024

11

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

31 March 2024

12

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2024

13

1 reference

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

31 March 2024

14

1 reference

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

31 March 2024

15

1 reference

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

31 March 2024

16

1 reference

Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.

31 March 2024

17

1 reference

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

31 March 2024

18

1 reference

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

31 March 2024

19

1 reference

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

31 March 2024

20

1 reference

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

31 March 2024

21

1 reference

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

31 March 2024

23

1 reference

Tuberculosis and treatment with infliximab

31 March 2024

25

1 reference

Extrapulmonary tuberculosis in the United States

31 March 2024

26

1 reference

Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice

31 March 2024

31

1 reference

Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis

31 March 2024

32

1 reference

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

31 March 2024

34

1 reference

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases

31 March 2024

35

1 reference

Interferon- and Tumor Necrosis Factor- Protect Mice from Invasive Aspergillosis

31 March 2024

36

1 reference

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

31 March 2024

41

1 reference

Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection

31 March 2024

43

1 reference

Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection

31 March 2024

46

1 reference

Clinical practice. Latent tuberculosis infection

31 March 2024

47

1 reference

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

31 March 2024

48

1 reference

Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States

31 March 2024

49

1 reference

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.

31 March 2024

50

1 reference

31 March 2024

Identifiers

DOI

10.1002/ART.11301

1 reference

9 August 2017

1 reference